Registry of Hospitalized Patients Treated With Fondaparinux
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 220
- 主要终点
- Venous Thromboembolism and Bleeding Events
研究概览
简要总结
Registry of Hospitalized patients at Brigham and Women's Hospital treated with Fondaparinux
详细描述
The use of antithrombotic agents in the hospital is the mainstay of therapy for the treatment or prophylaxis of venous thromboembolism (VTE) and acute coronary syndrome (ACS). Concern with the administration of heparins and risk for adverse sequelae has led to the development of newer, longer-acting agents. Fondaparinux offers once daily administration with only an extremely small risk of developing heparin induced thrombocytopenia.
Recent data have further demonstrated the efficacy and safety of Fondaparinux in VTE and ACS, expanding its use in clinical practice. We aim to: 1) determine how Fondaparinux is being used in a "real life" clinical setting, a tertiary-care academic medical center (BWH), and 2) assess the associated clinical outcomes at 90 days after initiation of Fondaparinux.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •BWH hospitalized patients receiving Fondaparinux
排除标准
- 未提供
结局指标
主要结局
Venous Thromboembolism and Bleeding Events
时间窗: 90 Days
次要结局
- Mortality(30 Days)